Risk Factors for Cytomegalovirus Infection After Allogeneic Hematopoietic Cell Transplantation in Malignancies: Proposal for Classification
- PMID: 29187429
- DOI: 10.21873/anticanres.12111
Risk Factors for Cytomegalovirus Infection After Allogeneic Hematopoietic Cell Transplantation in Malignancies: Proposal for Classification
Abstract
Aim: To identify and classify risk factors for cytomegalovirus (CMV) infection and disease in patients receiving allogeneic hematopoietic stem cell transplantation (allo-HSCT), treated mainly for acute leukemia.
Materials and methods: A literature search was performed;eligible trials were clinical studies assessing the risk factors for CMV infection or disease in multivariate analysis.
Results: Early reactivation in the setting of allo-HSCT took place mainly in patients without CMV prophylaxis, while late reactivation mainly in those patients who had completed previous prophylaxis or were on anti-CMV strategy based on pre-emptive prophylaxis. We propose classifying risk factors for CMV reactivation and CMV disease in patients after allo-HSCT as major and minor ones. Three major risk factors for CMV reactivation and CMV disease were found: (i) CMV-negative donor CMV-positive recipient serostatus, (ii) acute or chronic graft-versus-host disease, and (iii) unrelated or mismatched donor.
Conclusion: CMV reactivation should be regarded as a continuous function of recipient and donor CMV-seropositivity and recipient immune suppression, caused by conditioning, immunosuppressive therapy and human leukocyte antigen disparity between donor and recipient.
Keywords: CMV; acute leukemia; review; risk factors; transplantation.
Copyright© 2017, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.
Similar articles
-
Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.Biol Blood Marrow Transplant. 2015 Nov;21(11):2008-16. doi: 10.1016/j.bbmt.2015.07.019. Epub 2015 Jul 26. Biol Blood Marrow Transplant. 2015. PMID: 26211985
-
Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy.Transpl Infect Dis. 2010 Aug 1;12(4):322-9. doi: 10.1111/j.1399-3062.2010.00504.x. Epub 2010 May 11. Transpl Infect Dis. 2010. PMID: 20487414
-
Effect of Cytomegalovirus Reactivation on Relapse after Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Acute Leukemia.Biol Blood Marrow Transplant. 2016 Feb;22(2):300-306. doi: 10.1016/j.bbmt.2015.09.006. Epub 2015 Sep 11. Biol Blood Marrow Transplant. 2016. PMID: 26371373
-
The role of cytomegalovirus serostatus on outcome of hematopoietic stem cell transplantation.Curr Opin Hematol. 2014 Nov;21(6):466-9. doi: 10.1097/MOH.0000000000000085. Curr Opin Hematol. 2014. PMID: 25159712 Review.
-
Potential Beneficial Effects of Cytomegalovirus Infection after Transplantation.Front Immunol. 2018 Mar 1;9:389. doi: 10.3389/fimmu.2018.00389. eCollection 2018. Front Immunol. 2018. PMID: 29545802 Free PMC article. Review.
Cited by
-
Features of cytomegalovirus infection and evaluation of cytomegalovirus-specific T cells therapy in children's patients following allogeneic hematopoietic stem cell transplantation: A retrospective single-center study.Front Cell Infect Microbiol. 2022 Oct 20;12:1027341. doi: 10.3389/fcimb.2022.1027341. eCollection 2022. Front Cell Infect Microbiol. 2022. PMID: 36339340 Free PMC article.
-
CMV Infection Post Allogeneic Hematopoietic Stem Cell Transplantation in a Resource Limited Country.Indian J Hematol Blood Transfus. 2024 Jan;40(1):97-102. doi: 10.1007/s12288-023-01655-0. Epub 2023 Apr 20. Indian J Hematol Blood Transfus. 2024. PMID: 38312192 Free PMC article.
-
Impact of Primary Letermovir Prophylaxis Versus Preemptive Antiviral Therapy for Cytomegalovirus on Economic and Clinical Outcomes after Hematopoietic Cell Transplantation.Transplant Cell Ther. 2024 Aug;30(8):792.e1-792.e12. doi: 10.1016/j.jtct.2024.05.021. Epub 2024 Jun 3. Transplant Cell Ther. 2024. PMID: 38838781 Free PMC article.
-
CD34+ cell dose and CMV viremia after haploidentical hematopoietic stem cell transplantation: a retrospective study.Am J Transl Res. 2024 Sep 15;16(9):5130-5136. doi: 10.62347/SOPM3064. eCollection 2024. Am J Transl Res. 2024. PMID: 39398542 Free PMC article.
-
Risk factors and clinical outcomes of cytomegalovirus infection following haploidentical hematopoietic stem cell transplantation in patients with aplastic anemia: a single-center retrospective study.Front Med (Lausanne). 2025 Jan 29;11:1523909. doi: 10.3389/fmed.2024.1523909. eCollection 2024. Front Med (Lausanne). 2025. PMID: 39944817 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical